NasdaqGS:ASND
NasdaqGS:ASNDBiotechs

Did FDA’s TransCon CNP Review Delay Just Shift Ascendis Pharma’s (ASND) Investment Narrative?

In November 2025, Ascendis Pharma A/S disclosed that the FDA deemed its November 5 submission for TransCon CNP (navepegritide) in children with achondroplasia a major amendment, extending the PDUFA target action date by three months to February 28, 2026. This extension introduces additional regulatory review and timing uncertainty for a key pipeline asset that analysts had viewed as an important future growth driver. We’ll now examine how the extended PDUFA review for TransCon CNP reshapes...
NasdaqCM:SSII
NasdaqCM:SSIIMedical Equipment

Is SSII’s Budget-Friendly Surgical Robot Rerouting Its Long-Term Competitive Trajectory in Medtech?

SS Innovations International recently reported rapid growth in installations and procedures for its SSi Mantra 3 surgical robotic system, driven by its design features and affordability compared with existing options. Management highlighted that the system’s unique configuration and lower cost are helping it win surgeon adoption in procedures traditionally dominated by higher-priced robotic platforms. We’ll now examine how this expanding demand for the SSi Mantra 3 could shape SS Innovations...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

How Investors Are Reacting To Catalyst Pharmaceuticals (CPRX) Upgraded 2025 Sales Outlook And Easing Short Interest

In the past week, Catalyst Pharmaceuticals reported stronger-than-expected third-quarter results, with Firdapse and Agamree driving revenue outperformance and prompting the company to lift its full-year 2025 sales guidance across several products. An interesting angle for investors is that this fundamental improvement coincides with a recent reduction in short interest as a share of float, suggesting shifting sentiment among bearish traders. Now, we’ll examine how the upgraded 2025 sales...